L3VLUP
ProSign in

DFTX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DFTXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DFTX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterDFTXVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 2022none listed holders, n.a.25 holders, $18.1bn
Q3 2022none listed holders, n.a.22 holders, $18.4bn
Q4 2022none listed holders, n.a.28 holders, $18.4bn
Q1 2023none listed holders, n.a.26 holders, $21.4bn
Q2 2023none listed holders, n.a.27 holders, $24.7bn
Q3 2023none listed holders, n.a.33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 2024none listed holders, n.a.31 holders, $29.8bn
Q2 2024none listed holders, n.a.29 holders, $33.4bn
Q3 2024none listed holders, n.a.27 holders, $33.5bn
Q4 2024none listed holders, n.a.26 holders, $28.5bn
Q1 2025none listed holders, n.a.21 holders, $35.4bn
Q2 2025none listed holders, n.a.21 holders, $32.3bn
Q3 2025none listed holders, n.a.22 holders, $25.9bn
Q4 20251 holders, $40m26 holders, $31.8bn
Q1 20265 holders, $107m25 holders, $31.8bn
Q2 20269 holders, $1.1bn26 holders, $34.6bn
DFTX

Definium Therapeutics Inc

Holders
5
Reported value
$107m
Buyers
25
Sellers
1

Not ranked this quarter: its new positions are allocations in a new listing.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DFTX (1)

Brevan Howard Capital Management LP

Only VRTX (21)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Walleye Capital LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →